• Login
    View Item 
    •   Home
    • The Christie Research Publications Repository
    • All Christie Publications
    • View Item
    •   Home
    • The Christie Research Publications Repository
    • All Christie Publications
    • View Item
    JavaScript is disabled for your browser. Some features of this site may not work without it.

    Browse

    All of ChristieCommunitiesTitleAuthorsIssue DateSubmit DateSubjectsThis CollectionTitleAuthorsIssue DateSubmit DateSubjectsProfilesView

    My Account

    LoginRegister

    Local Links

    The Christie WebsiteChristie Library and Knowledge Service

    Statistics

    Display statistics

    The octreotide test dose is not a reliable predictor of the subsequent response to somatostatin analogue therapy in patients with acromegaly.

    • CSV
    • RefMan
    • EndNote
    • BibTex
    • RefWorks
    Thumbnail
    Name:
    76000.pdf
    Size:
    175.4Kb
    Format:
    PDF
    Description:
    From UNPAYWALL
    Download
    Authors
    Pokrajac, Ana
    Claridge, Andrew G
    Shakoor, S K Abdul
    Trainer, Peter J
    Affiliation
    Christie Hospital NHS Trust, Department of Endocrinology, Wilmslow Road, Withington, Manchester M20 4BX, UK.
    Issue Date
    2006-02
    
    Metadata
    Show full item record
    Abstract
    In many centres, a test dose (TD) of octreotide is administered before commencing somatostatin analogue therapy (SAT), although the merits of this procedure are uncertain. We have analysed the value of the GH response to a TD in predicting the efficacy of subsequent SAT in 47 patients with acromegaly (25 male, median age 51 years, range 20-82). The primary goal of SAT was a mean GH of < 5 mU/l. Median baseline GH was 19.3 mU/l (2.2-233 mU/l) and with the TD fell by 78% (35-98%) to a nadir of 4.2 mU/l (< 0.3-85 mU/l). Optimal predictive power was observed when GH fell to < 5 mU/l after the TD. With this criterion, the TD had a positive predictive value (PPV) of achieving the primary goal on SAT of 82% and a negative predictive value (NPV) of 50%. However, baseline GH was also highly predictive of the likelihood of successful SAT (GH < 5 mU/l). The GH response to the TD had PPV of 83% and NPV of 61% of normalising IGF-I on SAT. In summary, baseline GH and nadir after a TD are highly predictive of a good response to SAT; however, a poor response to a TD does not exclude an optimal response to SAT. Furthermore, failure to achieve biochemical control does not equate to no benefit, as biochemical improvement was seen in every patient; therefore, no patient should be deprived of octreotide therapy because of the result of a TD. In conclusion, our data indicate that the octreotide TD has no place in selecting patients for SAT.
    Citation
    The octreotide test dose is not a reliable predictor of the subsequent response to somatostatin analogue therapy in patients with acromegaly. 2006, 154 (2):267-74 Eur. J. Endocrinol.
    Journal
    European Journal of Endocrinology
    URI
    http://hdl.handle.net/10541/72648
    DOI
    10.1530/eje.1.02073
    PubMed ID
    16452540
    Type
    Article
    Language
    en
    ISSN
    0804-4643
    ae974a485f413a2113503eed53cd6c53
    10.1530/eje.1.02073
    Scopus Count
    Collections
    All Christie Publications

    entitlement

    Related articles

    • The value of an acute octreotide suppression test in predicting long-term responses to depot somatostatin analogues in patients with active acromegaly.
    • Authors: Karavitaki N, Botusan I, Radian S, Coculescu M, Turner HE, Wass JA
    • Issue date: 2005 Mar
    • Intravenous octreotide test predicts the long term outcome of treatment with octreotide-long-acting repeatable in active acromegaly.
    • Authors: Biermasz NR, Pereira AM, Smit JW, Romijn JA, Roelfsema F
    • Issue date: 2005 Jun
    • The nadir growth hormone after an octreotide test dose predicts the long-term efficacy of somatostatin analogue therapy in acromegaly.
    • Authors: Gilbert JA, Miell JP, Chambers SM, McGregor AM, Aylwin SJ
    • Issue date: 2005 Jun
    • Poor responses to a test dose of subcutaneous octreotide predict the need for adjuvant therapy to achieve 'safe' growth hormone levels.
    • Authors: Lindsay JR, McConnell EM, Hunter SJ, McCance DR, Sheridan B, Atkinson AB
    • Issue date: 2004
    • Limited predictive value of an acute test with subcutaneous octreotide for long-term IGF-I normalization with Sandostatin LAR in acromegaly.
    • Authors: de Herder WW, Taal HR, Uitterlinden P, Feelders RA, Janssen JA, van der Lely AJ
    • Issue date: 2005 Jul
    DSpace software (copyright © 2002 - 2025)  DuraSpace
    Quick Guide | Contact Us
    Open Repository is a service operated by 
    Atmire NV
     

    Export search results

    The export option will allow you to export the current search results of the entered query to a file. Different formats are available for download. To export the items, click on the button corresponding with the preferred download format.

    By default, clicking on the export buttons will result in a download of the allowed maximum amount of items.

    To select a subset of the search results, click "Selective Export" button and make a selection of the items you want to export. The amount of items that can be exported at once is similarly restricted as the full export.

    After making a selection, click one of the export format buttons. The amount of items that will be exported is indicated in the bubble next to export format.